SCHEMBL425129

SCHEMBL425129

CC(C)Oc1cccc(Cl)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.40
MCHR1 Q99705 1/20 0.40
CYP3A4 P08684 1/20 0.38
TSHR P16473 1/20 0.38
ALDH1A1 P00352 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
GAA P10253 1/20 0.37
IDH1 O75874 6/20 0.36
IDH2 P48735 4/20 0.36
GRM5 P41594 1/20 0.36
MAPT P10636 2/20 0.35
GABRA1 P14867 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35
HTR3E A5X5Y0 1/20 0.34
HTR3B O95264 1/20 0.34
HTR3A P46098 1/20 0.34
HTR3D Q70Z44 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2523502 0.84 KMT2A (0.42) MCHR1TSHRALDH1A1SMN1; SMN2GRM5
SCHEMBL27869168 0.84 MCHR1 (0.42) L3MBTL1MCHR1CYP3A4TSHRALDH1A1
SCHEMBL27852165 0.81 MCHR1 (0.45) L3MBTL1MCHR1CYP3A4TSHRALDH1A1
SCHEMBL27869215 0.80 L3MBTL1 (0.38) L3MBTL1MCHR1CYP3A4TSHRALDH1A1
SCHEMBL19510740 0.80 IDH1 (0.42) L3MBTL1CYP3A4TSHRALDH1A1SMN1; SMN2
SCHEMBL363302 0.79 CYP3A4 (0.38) L3MBTL1CYP3A4TSHRALDH1A1IDH1
SCHEMBL27852276 0.79 MCHR1 (0.45) L3MBTL1MCHR1CYP3A4TSHRALDH1A1
SCHEMBL27869174 0.78 L3MBTL1 (0.35) L3MBTL1MCHR1CYP3A4TSHRALDH1A1
SCHEMBL27869166 0.78 MCHR1 (0.48) L3MBTL1MCHR1CYP3A4TSHRALDH1A1
SCHEMBL28794497 0.78 MCHR1 (0.35) L3MBTL1MCHR1CYP3A4TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023283921-A1 DPD INHIBITOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 北京深蓝泰医药科技有限公司 2023-01-19 WO claimed
CN-107567443-B Biaryl derivatives as GPR120 agonists 株式会社LG化学 2023-04-28 CN disclosed
CN-115925679-A Biaryl derivatives as GPR120 agonists 株式会社LG化学 2023-04-07 CN disclosed
EP-3239143-B1 BIARYL DERIVATIVE AS GPR120 AGONIST LG CHEMICAL LTD (KR) 2023-03-22 EP disclosed
US-20220135574-A1 BIARYL DERIVATIVE AS GPR120 AGONIST LG CHEM, LTD. (KR) 2022-05-05 US disclosed
US-11261186-B2 Biaryl derivative as GPR120 agonist LG CHEM. LTD. (KR) 2022-03-01 US disclosed
CN-105392777-B Biaryl derivatives as GPR120 agonists 株式会社LG化学 2020-09-22 CN disclosed
EP-3013796-B9 BIARYL DERIVATIVES AS GPR120 AGONISTS LG CHEMICAL LTD (KR) 2020-07-01 EP disclosed
EP-3628661-A1 BIARYL DERIVATIVES AS GPR120 AGONISTS LG CHEM, LTD. (KR) 2020-04-01 EP disclosed
US-10221138-B2 Biaryl derivatives as GPR120 agonists LG CHEM, LTD. (KR) 2019-03-05 US disclosed
CN-105392777-A Biaryl derivatives as GRP120 agonists LG LIFE SCIENCES LTD 2016-03-09 CN disclosed
WO-2014209034-A1 BIARYL DERIVATIVES AS GPR120 AGONISTS LG LIFE SCIENCES LTD. (KR) 2014-12-31 WO disclosed
CN-102452978-A 2-chloro-substituted or unsubstituted aliphatic hydrocarbyloxypyridine and method for producing same CHONGQING KANGDING MEDICAL TECHNOLOGY CO LTD 2012-05-16 CN disclosed
EP-2417121-A1 4, 5-DIHYDRO-1H-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES Pfizer Inc. (US) 2012-02-15 EP disclosed
US-20120022058-A1 4,5-DIHYDRO-1H-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES PFIZER INC. 2012-01-26 US disclosed
WO-2010116282-A1 4, 5-DIHYDRO-LH-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES PFIZER INC. (US) 2010-10-14 WO disclosed
CN-1084735-C Substituted pyridin-2-ones and substituted pyridine-2-thiones as biocides ARCH CHEMICAL INDUSTRY CO (US) 2002-05-15 CN disclosed
CN-1133035-A Substituted pyridin-2-ones and substituted pyridine-2-thiones as biocides OLIN CORP (US) 1996-10-09 CN disclosed
US-4529800-A Novel process for the preparation of 2-halo-3-nitro-6-alkoxy-pyridines RUTGERSWERKE AKTIENGESELLSCHAFT (DE) 1985-07-16 US disclosed
EP-0102652-A1 Method for the preparation of pure 2-chloro-6-alkoxy-3-nitro-pyridines RÜTGERSWERKE AKTIENGESELLSCHAFT (DE) 1984-03-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220135574-A1 BIARYL DERIVATIVE AS GPR120 AGONIST GPR119, GLP1R, GIPR L3MBTL1 2990/4885MCHR1 587/4885CYP3A4 1149/4885
US-10221138-B2 Biaryl derivatives as GPR120 agonists GPR119, GLP1R, GIPR L3MBTL1 3522/4885MCHR1 588/4885CYP3A4 1368/4885
US-20120022058-A1 4,5-DIHYDRO-1H-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES NR3C2, REN, AGTR1 L3MBTL1 4869/4885MCHR1 1932/4885CYP3A4 753/4885
US-11261186-B2 Biaryl derivative as GPR120 agonist GPR119, GPR88, FFAR1 L3MBTL1 4242/4885MCHR1 530/4885CYP3A4 779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.